These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 21705122

  • 1. Reduction of plasma oxalate levels by oral application of Oxalobacter formigenes in 2 patients with infantile oxalosis.
    Hoppe B, Dittlich K, Fehrenbach H, Plum G, Beck BB.
    Am J Kidney Dis; 2011 Sep; 58(3):453-5. PubMed ID: 21705122
    [Abstract] [Full Text] [Related]

  • 2. Oxalobacter formigenes treatment combined with intensive dialysis lowers plasma oxalate and halts disease progression in a patient with severe infantile oxalosis.
    Pape L, Ahlenstiel-Grunow T, Birtel J, Krohne TU, Hoppe B.
    Pediatr Nephrol; 2020 Jun; 35(6):1121-1124. PubMed ID: 32107618
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria.
    Hoppe B, Groothoff JW, Hulton SA, Cochat P, Niaudet P, Kemper MJ, Deschênes G, Unwin R, Milliner D.
    Nephrol Dial Transplant; 2011 Nov; 26(11):3609-15. PubMed ID: 21460356
    [Abstract] [Full Text] [Related]

  • 4. Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis.
    Hoppe B, von Unruh GE, Blank G, Rietschel E, Sidhu H, Laube N, Hesse A.
    Am J Kidney Dis; 2005 Sep; 46(3):440-5. PubMed ID: 16129205
    [Abstract] [Full Text] [Related]

  • 5. Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: possible prevention by gut recolonization or enzyme replacement therapy.
    Sidhu H, Schmidt ME, Cornelius JG, Thamilselvan S, Khan SR, Hesse A, Peck AB.
    J Am Soc Nephrol; 1999 Nov; 10 Suppl 14():S334-40. PubMed ID: 10541258
    [Abstract] [Full Text] [Related]

  • 6. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1.
    Hoppe B, Beck B, Gatter N, von Unruh G, Tischer A, Hesse A, Laube N, Kaul P, Sidhu H.
    Kidney Int; 2006 Oct; 70(7):1305-11. PubMed ID: 16850020
    [Abstract] [Full Text] [Related]

  • 7. A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.
    Hoppe B, Niaudet P, Salomon R, Harambat J, Hulton SA, Van't Hoff W, Moochhala SH, Deschênes G, Lindner E, Sjögren A, Cochat P.
    Pediatr Nephrol; 2017 May; 32(5):781-790. PubMed ID: 27924398
    [Abstract] [Full Text] [Related]

  • 8. Oxalobacter formigenes treatment confers protective effects in a rat model of primary hyperoxaluria by preventing renal calcium oxalate deposition.
    Verhulst A, Dehmel B, Lindner E, Akerman ME, D'Haese PC.
    Urolithiasis; 2022 Apr; 50(2):119-130. PubMed ID: 35122487
    [Abstract] [Full Text] [Related]

  • 9. Stable expression of the oxc and frc genes from Oxalobacter formigenes in human embryo kidney 293 cells: implications for gene therapy of hyperoxaluria.
    Ye ZQ, Kong DB, Chen ZQ, Yao LF, Guo H, Yu X, Liu GL, Yang WM.
    Int J Mol Med; 2007 Oct; 20(4):521-6. PubMed ID: 17786282
    [Abstract] [Full Text] [Related]

  • 10. Intestinal Oxalobacter formigenes colonization in calcium oxalate stone formers and its relation to urinary oxalate.
    Troxel SA, Sidhu H, Kaul P, Low RK.
    J Endourol; 2003 Apr; 17(3):173-6. PubMed ID: 12803990
    [Abstract] [Full Text] [Related]

  • 11. Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria Type 1 and end-stage renal disease: a Phase II study.
    Hoppe B, Pellikka PA, Dehmel B, Banos A, Lindner E, Herberg U.
    Nephrol Dial Transplant; 2021 Jul 23; 36(8):1464-1473. PubMed ID: 32810261
    [Abstract] [Full Text] [Related]

  • 12. A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.
    Milliner D, Hoppe B, Groothoff J.
    Urolithiasis; 2018 Aug 23; 46(4):313-323. PubMed ID: 28718073
    [Abstract] [Full Text] [Related]

  • 13. Sel1-like proteins and peptides are the major Oxalobacter formigenes-derived factors stimulating oxalate transport by human intestinal epithelial cells.
    Arvans D, Chang C, Alshaikh A, Tesar C, Babnigg G, Wolfgeher D, Kron S, Antonopoulos D, Bashir M, Cham C, Musch M, Chang E, Joachimiak A, Hassan H.
    Am J Physiol Cell Physiol; 2023 Jul 01; 325(1):C344-C361. PubMed ID: 37125773
    [Abstract] [Full Text] [Related]

  • 14. Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria.
    Sidhu H, Hoppe B, Hesse A, Tenbrock K, Brömme S, Rietschel E, Peck AB.
    Lancet; 1998 Sep 26; 352(9133):1026-9. PubMed ID: 9759746
    [Abstract] [Full Text] [Related]

  • 15. Infrequency of colonization with Oxalobacter formigenes in inflammatory bowel disease: possible role in renal stone formation.
    Kumar R, Ghoshal UC, Singh G, Mittal RD.
    J Gastroenterol Hepatol; 2004 Dec 26; 19(12):1403-9. PubMed ID: 15610315
    [Abstract] [Full Text] [Related]

  • 16. ePHex: a phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria.
    Ariceta G, Collard L, Abroug S, Moochhala SH, Gould E, Boussetta A, Ben Hmida M, De S, Hunley TE, Jarraya F, Fraga G, Banos A, Lindner E, Dehmel B, Schalk G.
    Pediatr Nephrol; 2023 Feb 26; 38(2):403-415. PubMed ID: 35552824
    [Abstract] [Full Text] [Related]

  • 17. Association of intestinal oxalate-degrading bacteria with recurrent calcium kidney stone formation and hyperoxaluria: a case-control study.
    Tavasoli S, Alebouyeh M, Naji M, Shakiba Majd G, Shabani Nashtaei M, Broumandnia N, Basiri A.
    BJU Int; 2020 Jan 26; 125(1):133-143. PubMed ID: 31145528
    [Abstract] [Full Text] [Related]

  • 18. Liver cell transplantation in severe infantile oxalosis--a potential bridging procedure to orthotopic liver transplantation?
    Beck BB, Habbig S, Dittrich K, Stippel D, Kaul I, Koerber F, Goebel H, Salido EC, Kemper M, Meyburg J, Hoppe B.
    Nephrol Dial Transplant; 2012 Jul 26; 27(7):2984-9. PubMed ID: 22287658
    [Abstract] [Full Text] [Related]

  • 19. Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter.
    Hatch M, Gjymishka A, Salido EC, Allison MJ, Freel RW.
    Am J Physiol Gastrointest Liver Physiol; 2011 Mar 26; 300(3):G461-9. PubMed ID: 21163900
    [Abstract] [Full Text] [Related]

  • 20. Hyperoxaluria, hypocitraturia, hypomagnesiuria, and lack of intestinal colonization by Oxalobacter formigenes in a cervical spinal cord injury patient with suprapubic cystostomy, short bowel, and nephrolithiasis.
    Vaidyanathan S, von Unruh GE, Watson ID, Laube N, Willets S, Soni BL.
    ScientificWorldJournal; 2006 Apr 06; 6():2403-10. PubMed ID: 17619709
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.